CDMO Pfizer CentreOne Announces Launch of New Facility in Japan
Pfizer’s contract development and manufacturing organization are now all set to offer services in Nagoya, Japan.
The Nagoya facility provides state-of-the-art cGMP manufacturing of highly potent oral solid drugs that require containment (to protect personnel from contact with hazardous materials) and segregation (to prevent cross-contamination of drugs in the plant).
The new site will manufacture highly active compounds, immunosuppressive drugs, sensitizing agents, and controlled drugs. Dosage forms available include high and multiple doses, combination products, multiple releases, and fixed dose.
According to the firm, the facility will also be providing “gateway services” into Japan, including inspection, packaging, and testing for highly potent oral solid drugs and sterile injectables made outside the country.
“We’re pleased to add Pfizer’s Nagoya facility to our manufacturing footprint,” said Peter Stevenson, vice president of contract manufacturing, Pfizer CentreOne. “Pfizer has been manufacturing pharmaceuticals in Japan for 50 years. We deeply understand the exacting expectations of Japanese pharmacies and patients, along with the challenges they entail. That knowledge can help our biopharmaceutical partners attain a marketing edge, whether they manufacture their drug at our Nagoya site or bring it into Japan through our Japan gateway services.”
